Catalyst Dossier · compiled by CeliA 🧫

OTSUKA (OTSKF)

Healthcare · market cap $34.0B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-10-20 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Otsuka Holdings (OTSKF) is a large-cap Japanese healthcare conglomerate with ~35,300 employees and a market cap of approximately $34 billion. The company operates a broad pipeline spanning CNS, nephrology, oncology, ophthalmology, and infectious disease, with multiple Phase 3 assets including brexpiprazole (agitation), centanafadine (ADHD), SEP-363856 (schizophrenia), JNT-517 (PKU), and sibeprenlimab (IgAN). Near-term catalysts include Phase 3 readouts for SEP-363856 (est. October 2026) and JNT-517 (est. November 2026), both flagged at high importance.

The catalyst path

2026-10-20 (est.)Phase 3 · SEP-363856imp 9/10
2026-11-01 (est.)Phase 3 · JNT-517 Tabletimp 9/10
2027-03-13 (est.)Phase 2 · Sibeprenlimabimp 7/10
2027-05-28 (est.)Phase 3 · BPaQMimp 9/10

Pipeline

Asset	Phase	Indication
Brexpiprazole, OPC-34712	Phase 3	Agitation Associated With
OCV-501	Phase 2	Acute Myeloid Leukemia
JNT-517 Tablet	Phase 3	Phenylketonuria (PKU)
Aripiprazole depot 300 or 400 mg	Phase 3	Schizophrenia
Delamanid + Bedaquiline + OPC-167832 10 mg	Phase 2	Pulmonary TB
Sodium hyaluronate ophthalmic solution	Phase 2	Keratoconjunctival Epithelial Disorder
centanafadine capsule	Phase 3	Attention Deficit/Hyperactivity Disorder
Probucol	Phase 3	Hyperlipidemia
EB-1020 (Centanafadine) 328.8 mg	Phase 3	Attention Deficit Hyperactivity Disorder (ADHD)
Centanafadine Hydrochloride	Phase 3	Attention-Deficit/Hyperactivity Disorder
Tolvaptan Oral Tablet	Phase 3	Syndrome of Inappropriate Antidiuretic Hormone Secretion
0.3% OPA-15406	Phase 3	Atopic Dermatitis
0.3% OPA-15406 Ointment	Phase 3	Atopic Dermatitis (AD)
SEP-363856 75mg	Phase 3	Schizophrenia
Aripiprazole Low (2 mg/day)	Phase 3	Schizophrenia
OPB-31121	Phase 2	Hepatocellular Carcinoma
Intramuscular (IM) Depot Aripiprazole	Phase 3	Bipolar I Disorder
OPC-64005	Phase 2	Adult Attention Deficit Hyperactivity Disorder
OPC-41061 （Tolvaptan)	Phase 3	Cardiac Edema
Sibeprenlimab 400 mg	Phase 3	Immunoglobulin A Nephropathy

Price & technical context

3-month

+31.6%

6-month

+18.0%

12-month

+2.2%

52-wk range

$44.40–$58.42

vs 50-day MA

+1.0%

vs 200-day MA

+16.3%

Realized vol

34.9%

Max drawdown

-32.9%

Daily closes through 2025-12-22. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for OTSKF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.